What’s Ahead for Polarityte Inc (NASDAQ:PTE) After Less Shorted Shares?

The stock of Polarityte Inc (NASDAQ:PTE) registered a decrease of 6.15% in short interest. PTE’s total short interest was 7.33 million shares in July as published by FINRA. Its down 6.15% from 7.81 million shares, reported previously. With 196,200 shares average volume, it will take short sellers 37 days to cover their PTE’s short positions. The short interest to Polarityte Inc’s float is 64.7%.

The stock increased 0.98% or $0.05 during the last trading session, reaching $5.64. About 80,896 shares traded. PolarityTE, Inc. (NASDAQ:PTE) has declined 70.00% since July 12, 2018 and is downtrending. It has underperformed by 74.43% the S&P500.

PolarityTE, Inc. operates as a biotechnology and regenerative biomaterials firm in the United States. The company has market cap of $136.93 million. The firm focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences. It currently has negative earnings.

More notable recent PolarityTE, Inc. (NASDAQ:PTE) news were published by: Nasdaq.com which released: “Implied Volatility Surging for PolarityTE (PTE) Stock Options – Nasdaq” on May 20, 2019, also Benzinga.com with their article: “Benzinga’s Top Upgrades, Downgrades For July 8, 2019 – Benzinga” published on July 08, 2019, Nasdaq.com published: “GasLog Partners LP Announces New Multi-Year Charter Agreement with Gunvor – Nasdaq” on June 14, 2019. More interesting news about PolarityTE, Inc. (NASDAQ:PTE) were released by: Globenewswire.com and their article: “Singapore’s Wealth Landscape 2018-2022: Wealth Held by HNW Investors Will Grow Strongly Over the Review Period – GlobeNewswire” published on June 26, 2019 as well as Nasdaq.com‘s news article titled: “Non-renounceable rights issue and cleansing notice – NASDAQ.com – Nasdaq” with publication date: June 18, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.